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Aims:  There  are conﬂicting  data  regarding  the clinical  beneﬁts  of  device-based  remote  moni-
toring (RM).  We  sought  to  assess  the  effect  of  device-based  RM  on long-term  clinical  outcomes
in recipients  of  implantable  cardioverter-deﬁbrillators  (ICDs).
Methods: We  assessed  the incidence  of  adverse  cardiac  events,  overall  mortality  and  device
therapy efﬁcacy  and safety  in a  propensity  score-matched  cohort  of  patients  under  RM  compared
to patients  under  conventional  follow-up.  Data on  hospitalizations,  mortality  and  cause  of  death
were systematically  assessed  using  a  nationwide  healthcare  platform.  The  primary  outcome  was
time to  a  composite  outcome  of  ﬁrst  hospital  admission  for  heart  failure  or  cardiovascular  death.
Results: Of  a  total  of  923  implantable  device  recipients,  164 matched  patients  were  identiﬁed
(84 under  RM,  84  under  conventional  follow-up).  The  mean  follow-up  was  44  months  (range
1-123). There  were  no  signiﬁcant  differences  regarding  baseline  characteristics  in the  matched
cohorts. Patients  under  RM  had  a  signiﬁcantly  lower  incidence  of  the  primary  outcome  (haz-
ard ratio  [HR]  0.42,  conﬁdence  interval  [CI]  0.20-0.88,  p=0.022);  there  was  a non-signiﬁcant
trend towards  lower  overall  mortality  (HR  0.53,  CI  0.27-1.04,  p=0.066).  No  signiﬁcant  dif-
ferences  between  cohorts  were  found  regarding  appropriate  therapies  (RM vs.  conventional
follow-up,  8.1 vs.  8.2%,  p=NS)  or  inappropriate  therapies  (6.8  vs.  5.0%,  p=NS).
∗ Corresponding author.
E-mail address: gfportugal@gmail.com (G. Portugal).
http://dx.doi.org/10.1016/j.repc.2016.08.009
0870-2551/© 2017 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espan˜a,  S.L.U. All  rights reserved.21 4 049
Document downloaded from http://www.elsevier.es, day 24/05/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
190  G. Portugal  et al.
Conclusion:  In  a  propensity  score-matched  cohort  of  ICD  recipients  with  long-term  follow-up,
RM was  associated  with  a  lower  rate  of a combined  endpoint  of hospital  admission  for  heart
failure or  cardiovascular  death.









O efeito  da  monitorizac¸ão remota  em  eventos  cardíacos  adversos  numa  amostra
emparelhada  por propensity-score  matching
Resumo
Objetivos:  Existem  dados  contraditórios  acerca  dos  benefícios  clínicos  da  monitorizac¸ão  remota
(MR). Os  autores  procuraram  aferir  o efeito  da  MR  de dispositivos  cardíacos  implantáveis  em
eventos  clínicos  a  longo  prazo.
Métodos:  Os autores  avaliaram  a  incidência  de  eventos  cardíacos  adversos,  mortalidade  global,
e a  eﬁcácia  e seguranc¸a das terapêuticas  entregues  pelo  dispositivo  numa  amostra  de pacientes
portadores  de  cardioversor-desﬁbrilhador  implantável  (CDI)  após  emparelhamento  por  propen-
sity score,  comparando  doentes  sob  MR  com  doentes  em  seguimento  convencional.  Dados
relativos  a  hospitalizac¸ões,  mortalidade  e causa  de morte  foram  sistematicamente  avaliados
com recurso  à  Plataforma  de Dados  de Saúde.  A  análise  primária  consistiu  no  tempo  até  um
evento composto  de  internamento  por  insuﬁciência  cardíaca  (IC)  ou morte  cardiovascular.
Resultados:  Num  total  de  923 portadores  de dispositivos  cardíacos,  identiﬁcámos  164  pacientes
emparelhados  (84  sob  MR,  84  sob  seguimento  convencional.  O  tempo  médio  de seguimento  foi
44 meses  (entre  1-123  meses).  Não  se  observaram  diferenc¸as  signiﬁcativas  nas  características
basais entre  os dois  grupos  após  emparelhamento  por  propensity  score.  Doentes  sob  MR  tiveram
uma incidência  signiﬁcativamente  menor  do  evento  composto  de  internamento  por  IC  ou  morte
de causa  cardiovascular  (hazard  ratio  [HR]  0,42;  intervalo  de  conﬁanc¸a  [IC]  0,20-0,88;  p=0,022);
houve uma tendência  não  estatisticamente  signiﬁcativa  para  uma  menor  mortalidade  global
(HR 0,53;  IC  0,27-1,04;  p=0,066).  Não  se  observaram  diferenc¸as  entre  grupos  relativamente
a terapêuticas  apropriadas  (MR  versus  seguimento  convencional;  8,1  versus  8,2%,  p=NS)  ou
terapêuticas  inapropriadas  (6,8  versus  5,0%,  p=NS).
Conclusão:  Numa  amostra  emparelhada  por  propensity  score  de portadores  de CDI,  a  MR
associou-se  a  uma  menor  incidência  de um  evento  composto  de internamento  por  IC ou morte
cardiovascular  a  longo  prazo.
©  2017  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Todos  os
direitos reservados.
Introduction
Technological  developments  and  expanded  indications
have  resulted  in a  large population  of  recipients  of
implantable  electronic  cardiac  devices,  including  a  signif-
icant  increase  in  the  number  of  patients  with  implantable
cardioverter-deﬁbrillators  (ICDs).  This  growing  population
represents  a unique  challenge  regarding  follow-up,  requir-
ing  an  experienced  team  with  in-depth  knowledge  of  device
programming  and potential  complications.1 To  date,  opti-
mal  clinical  resource  allocation  is  not  established  regarding
appropriate  follow-up  for  these  patients.
In  this  context,  remote  monitoring  (RM)  is  poised  to  be
a  valuable  tool  in the intensive  and  continuous  follow-up
of ICD  patients.  Published  data  support  the  safety  and efﬁ-
cacy  of this  intervention.1 However,  data  regarding  potential
clinical  beneﬁts  are scarce,  with  short  follow-up  periods  and
mainly  limited  to  speciﬁc  ICD  brands.
In  this  study  we  aimed  to  assess  the long-term  clinical
beneﬁts  of  RM  in  a  population  of  ICD  patients  for primary
prevention  of  sudden  cardiac  death.  To this  end,  we  sought
to  investigate  the effect  of  RM  on  hospital  admissions  for
heart  failure  (HF)  and  cardiovascular  death.
Methods
Study  population
We  performed  a propensity-matched  retrospective  cohort
study  of  consecutive  patients  referred  to a tertiary  center
for implantation  of  an ICD  for primary  prevention  who  under-
went  implantation  between  December  2002  and  October
2014.
Implantable  cardioverter-deﬁbrillator  implantation
Implantation  of an ICD  was  performed  according  to
international  guidelines2 for  patients  with  systolic  dys-
function  or  primary  channelopathies.  Implantation  in the
setting  of hypertrophic  cardiomyopathy  was  performed
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according  to  disease-speciﬁc  guidelines.3 Patients  indicated
for  implantation  for secondary  prevention  or  with  concur-
rent  implantation  of  a  cardiac  resynchronization  therapy
(CRT)  device  were  excluded.  ICD  patients  who  underwent
an  upgrade  to  a CRT  system  during follow-up  were  censored
for  analysis  after  the  procedure.
Remote  monitoring  and conventional  follow-up
RM  was  offered  to patients  whenever  available  as  offered
by  the  device  manufacturer,  with  the  patient’s  informed
consent.  The  equipment  was  provided  free  of  charge  at
the  ﬁrst  outpatient  visit  after  ICD  implantation.  Patients
were  then  scheduled  for  a hospital  visit  every  12  months,
with  transmissions  performed  every  three  months  during
the  study  period.  Reports  were  reviewed  by  trained  techni-
cians  who  would  alert  the attending  physician  if there  were
relevant  events.  Additionally,  RM  alerts were  transmitted
in  response  to  abnormal  events  such  as  delivered  shocks,
detection  of atrial  ﬁbrillation  episodes  or  abnormal  values
of  the  various  ICD  parameters.  In this  case,  patients  were
summoned  in  the  following  48  hours  for  an in-person  consul-
tation  with  an electrophysiologist  in order  to  review  the
episode.
Conventional  follow-up  consisted  of a patient  visit  one
month  after  implantation  and  every  four  months  there-
after.  Device  interrogation  was  performed  at  all visits,  and
relevant  events  (e.g.  changes  in lead  impedance  or  other
parameters,  detection  of  atrial  ﬁbrillation  or  appropriate
or  inappropriate  therapies)  were  recorded.  The  patient  was
then  observed  by  an electrophysiologist,  and  changes  in
device  programming,  reintervention,  drug therapy  or  indi-
cation  for  ablation  were  employed  as  deemed  appropriate.
Data  collection
Data  on  arrhythmic  events,  device  programming  and appro-
priate  and  inappropriate  ICD  therapies  were  prospectively
entered  into  a database  consisting  of  all  patients.  These
records  were  then  assessed  at the time  of  this study  for
possible  missing  data  and  completed  whenever  possible.
Patients  were  considered  lost  to  follow-up  when the  last
outpatient  visit  was  >18  months  previously  with  no  further
scheduled  visits.
Propensity  score  matching
To control  for  the nonrandom  assignment  of patients,  a logis-
tic  regression  model  was  constructed  that predicted  the
likelihood  that  a  patient  would  be  under  RM  and matched
patients  in  each  cohort  by this  score. The  explanatory
variables  used  were baseline  characteristics  including  age,
gender,  etiology  of cardiac  disease,  left ventricular  ejection
fraction  (LVEF)  and  New  York  Heart  Association  (NYHA)  class.
To  ensure  close  matches,  the  difference  in the calculated
propensity  score  was  required  to  be  below  0.005 between
paired  subjects.
Primary  outcome
The  primary  endpoint  was  time  to  a composite  endpoint
of  ﬁrst  hospital  admission  for  HF  or  cardiovascular  death.
Information  on  hospitalizations  and  mortality  was  accessed
via  a  nationwide  healthcare  platform  (Plataforma  de  Dados
de  Saúde) that  holds the  records  of  nine  out of  10  of the
referring  hospitals  and  the National  Registry  on  Mortality.
Patient  records  were  systematically  reviewed,  and  infor-
mation  was  collected  regarding  hospital  admissions  and
all-cause  mortality.  The  cause  of  hospitalization  was  deter-
mined  according  to  an International  Classiﬁcation  of  Disease
9  (ICD-9)-based  system  as  coded  by  the  discharging  hospi-
tal.  Likewise,  cause  of  mortality  was  determined  according
to  the same  ICD-9-based  coding.  The  physician  responsible
for  assessing  study  outcomes  was  blinded  to  the  modality  of
follow-up  (RM  vs.  in-ofﬁce).
In  addition,  the incidence  of  appropriate  and  inappropri-
ate  device  therapies  was  compared  between  the matched
cohorts.
Statistical  analysis
Continuous  variables  were expressed  as  mean  and standard
deviation  when  they followed  a normal  distribution,  and
as  median  and  interquartile  range  otherwise.  Qualitative
variables  were  expressed  as  frequency  and  percentage.
Baseline  comparisons  were  performed  using the chi-square
test  for  qualitative  data  and  the Student’s  t  test  for  contin-
uous  variables  for unmatched  subjects  and  for  differences
between  groups  in matched  pairs.
Analysis  of  the  primary  outcome  of  time  to  admission  for
HF  or  cardiovascular  death  was  performed  by  Kaplan-Meier
curves,  the log-rank  test  for  comparisons  and  a  Cox pro-
portional  hazards  model  for calculation  of  the hazard  ratio
(HR).  A  two-sided  p-value  <0.05  was  considered  statistically
signiﬁcant.  All statistical  analyses  were  performed  using  the
software  package  STATA 12 (Statacorp).
Results
Study  population
We identiﬁed  a  total  of  923 patients  who  received  an ICD
during  this  period.  Of  these,  611 patients  were  excluded  on
the  basis  of  concomitant  CRT  (n=473)  or  implantation  in the
setting  of secondary  prevention  (n=138).  Patients  who  were
under RM  were  more  frequently  male,  older,  had  a  lower
LVEF,  and  were more  likely  to  have  an ischemic  etiology.
After propensity  score  matching,  we  identiﬁed
168  patients  corresponding  to  84  matched  pairs  who
remained  in the study  population.  There  were  no  signiﬁcant
differences  regarding  clinically  signiﬁcant  baseline  charac-
teristics  between  the two  cohorts.  Baseline  characteristics
after  propensity  score  matching  are presented  in Table  1.
Mean  LVEF  was  28.4%,  with  no  difference  between  groups
(RM  vs.  controls  28.9±9.6%  vs.  28.0±8.8%,  p=NS).  No  signif-
icant  differences  were  found regarding  age  at implantation
(56.9±1.3  vs.  57.9±1.1  years,  p=NS).
Most patients  had an indication  for  ICD in primary
prevention  in  the setting  of  left  ventricular  systolic
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Table  1  Baseline  characteristics  after  propensity  score  matching.
Remote  monitoring  Standard  care  p
No.  84  (50%) 84  (50%)
Age at  implantation  (years)  60.1±11.3  59.7±13.4  NS
Male 73  (86.9%)  74  (88.1%)  NS
LVEF (%)  28.9±9.7  28.0±8.8  NS
Etiology  NS
Ischemic  53  (63.1%)  52  (61.9%)
DCM 24  (28.6%)  25  (29.8%)
HCM 1  (1.2%)  5  (5.9%)
Brugada  syndrome 2  (2.4%)  1  (1.2%)
Other 3  (3.6%) 1  (1.2%)
NYHA class  NS
I 11  (13.1%)  10  (11.9%)
II 60  (71.4%)  63  (75.9%)
III 13  (15.5%)  11  (13.1%)
IV 0  (0%)  0  (0%)
Device brand <0.001
Biotronik  39  (46.4%) 4  (4.7%)
Boston  Scientiﬁc 7  (8.3%) 18  (21.2%)
Medtronic  18  (21.4%) 29  (34.1%)
Sorin 18  (21.4%) 22  (25.9%)
St. Jude  Medical 2  (2.4%) 11  (12.9%)
Device type
Single  chamber  80  (95.2%)  79  (94.0%)
Dual chamber  4  (4.8%)  5  (6.0%)
DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; LVEF: left ventricular ejection fraction; NYHA: New York Heart
Association.
dysfunction  (91.7%).  The  etiology  was  ischemic  cardiomy-
opathy  in  62.5%,  idiopathic  dilated  cardiomyopathy  in 29.2%,
hypertrophic  cardiomyopathy  in  3.6%,  Brugada  syndrome  in
1.8%  and  other  etiologies  in 3.0%  (one  patient  with  hyper-
tensive  heart  disease,  one  with  congenital  heart  disease,
two  with  valvular  heart  disease  and  one  with  left  ventricular
non-compaction  cardiomyopathy).
Follow-up
Mean  follow-up  was  44  months  (interquartile  range  20-66),
with  no  patients  lost  to  follow-up  during  the 12-year
study  period.  Mean  follow-up  duration  was  similar  between
cohorts  (43.0±29.8 months  for conventional  follow-up  vs.
46.1±27.9  months  for RM,  p=NS).  Data  on  the primary  out-
come  were  available  for  all  168 patients,  and were  used to
calculate  the  Kaplan-Meier  failure  estimates.
Study outcomes
RM  was  signiﬁcantly  associated  with  a lower  incidence  of
the  primary  outcome  of  hospital  admission  for HF  or  cardio-
vascular  death  (HR 0.42,  conﬁdence  interval  [CI]  0.20-0.88,
p=0.022).  This  difference,  manifested  early  during  follow-
up  and  increasing  throughout  the study  period,  suggests  a
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Figure  1  Kaplan-Meier  plot  of  incidence  of  the  primary  end-
point  (composite  outcome  of  hospital  admission  for  heart  failure
or cardiovascular  death).  Patients  under  remote  monitoring
(red)  had  a  signiﬁcantly  lower  incidence  (log-rank  test  p=0.018).
FUP: follow-up.
In addition,  the  effect  of  RM  on  overall  mortality  was
assessed.  Although  we did  not  ﬁnd  a signiﬁcant  difference
between  groups,  there  was  a  trend  toward  lower  mortality
in  the RM  group  (HR 0.53,  CI  0.27-1.04,  p=0.066).
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Figure  2  Incidence  of  appropriate  device  therapies  under
remote  monitoring  and  conventional  follow-up.  No signiﬁcant
difference  was  observed  between  cohorts,  suggesting  similar
efﬁcacy  of  the  antitachycardia  interventions  of  implantable
cardioverter-deﬁbrillators  in  both  groups.
To  test  whether  increased  availability  of RM  in recent
years  could  explain  the improved  outcomes  in these
patients,  we  controlled  for the  effect  of  year  of  implantation
by  patients  into  quartiles  according  to  year  of  implantation.
We  found  no  effect  of  year of  implantation  on  overall  sur-
vival  (log  rank,  p=0.177)  or  on  the  effect  of  RM  on  mortality
(p  for  interaction=0.384).
To  study  the  effectiveness  and safety  of  ICD  therapies,
we  analyzed  the  rate  of device  therapies  (shock  or  anti-
tachycardia  pacing)  during the study  period.  We  found  no
signiﬁcant  difference  between  the  incidence  of  appropri-
ate  device  therapies  (8.1 vs.  8.2 per  100  person/years,
p=NS,  Figure  2)  or inappropriate  therapies  (6.8  vs.  5.0  per
100  person/years,  p=NS).
Discussion
In  this  long-term  study  of two  modalities  of device  follow-
up  in  ICD  recipients,  we  found  a signiﬁcantly  lower  rate  of
a  combined  endpoint  of  unplanned  hospital  admission  for
HF  and  cardiovascular  mortality  in patients  under  RM.  The
overall  rate  of death  was  not signiﬁcantly  different  between
cohorts,  although  there  was  a numerical  trend  toward  lower
overall  mortality  in  patients  under  RM.  In  addition,  the  efﬁ-
cacy  and  safety  of  ICD  implantation  did  not differ  between
groups,  with  a  similar  rate  of appropriate  and  inappropriate
therapies  during  the study  period.
Our  study  cohort  consisted  of  unselected  all-comers  with
indication  for  ICD  implantation  for  primary  prevention  of
sudden  cardiac  death.  To  validate  our  ﬁndings  and adjust for
the  potential  confounding  effect  of baseline  characteristics,
we  performed  a propensity  score-matched  analysis  which
successfully  attained  a  balanced  cohort  of  patients.
As  previously  stated,  there  was  no  formal  randomization
of  patients,  with  RM  instituted  according  to  an independent
external factor,  in this  case  the  availability  of  the RM  hard-
ware  as offered  by  the device  manufacturer.  This  led  to
some  imbalance  in the distribution  of device  brands  between
patients  under  RM  or  conventional  follow-up.
Data  were  available  on  hospital  admissions  and mortality
for  the  entirety  of  our  cohort,  and  cause  of  death  or  hospi-
talization  was  assessed  as described  in  the Methods  section.
Patients  were  followed  for  up  to  12  years,  with  a  consistent
beneﬁt  of  RM  being  seen  throughout  follow-up.
Contemporary  wireless  RM  systems  avoid  the need  for
manual  wanded  transmissions  and  perform  automatic  trans-
missions  requiring  minimal  patient  input.  Furthermore,
there  are recognized  gains  in  resource  efﬁciency,  and  some
clinical  beneﬁts  have  also  been  demonstrated  in  clinical  tri-
als.  The  mechanisms  whereby  RM may  lead  to  improved
patient  outcomes,  as  assessed  by  these studies,  include
better adherence  to follow-up  and a  faster  time  to  physi-
cian  assessment  after  event  occurrence,4 lower  incidence
of  atrial  ﬁbrillation  and stroke-related  hospital  admissions,5
and  reduced  length  of  hospital  stay.  Other  beneﬁts  include
therapy  guided  by  intrathoracic  impedance  and  monitoring
of  ventricular  arrhythmias.
Most  studies  on  RM  have  been  underpowered  to  effec-
tively  assess  clinical  outcomes,  due  to  small  numbers  of
recruited  patients  or  short  duration  of  follow-up.  Recently,
the  PREDICT-RM  trial  demonstrated  reductions  in all-cause
rehospitalization  and  all-cause  mortality  in a large  cohort
of  patients  after new ICD implantation  who  underwent  RM
during  follow-up.6 In the IN-TIME  study,  Hindricks  et  al.7
randomized  716 patients  with  left ventricular  dysfunction
who  received  an ICD  (with  or  without  CRT)  to  automatic,
daily,  implant-based  telemonitoring  vs.  conventional  follow-
up  in a single-blinded  design.  After  one  year,  patients
under  RM  had a lower  composite  score  of  all-cause  mor-
tality,  admission  for  HF,  change  in NYHA  class,  and patient
global  self-assessment.  The  secondary  outcome  of  all-cause
death  was  signiﬁcantly  lower  in  the RM  group  (10  vs.
27  patients).
The  ALTITUDE  Survival  Study8 was  a registry-based  study
which  assessed  the  long-term  survival  of 194  006 recipients
of  Boston  intracardiac  ICD  and CRT  devices.  Patients  who
were  under  RM  follow-up  with  transmission  of information  to
the  LATITUDE  network  had  signiﬁcantly  improved  long-term
survival,  with  a 50%  relative  risk  reduction  in overall  mortal-
ity  (HR  0.56  for  ICD recipients;  HR 0.45  for CRT  recipients).
In  addition,  the recently  published  EFFECT  study,9 a prospec-
tive,  observational  trial  of  RM  in patients  treated  by  ICD-CRT
implantation,  also  showed an improvement  in the combined
endpoint  of  death  or  cardiovascular  hospitalization.
Not  all  studies  on  the effect  of  RM  on mortality  have
been  positive.  The  TELE-HF  trial10 randomized  1653  high-
risk  patients  to  telephone  telemonitoring  or  conventional
follow-up.  The  main  outcome  of  all-cause  mortality  or  rehos-
pitalization  at 180  days  was  not  signiﬁcantly  improved.
However,  adherence  to  and  frequency  of use  of  RM  may
have  a  signiﬁcant  impact  on  its  clinical  effect.  A recently
published  systematic  review  and meta-analysis11 of  clinical
outcomes  in randomized  controlled  trials  of  RM vs.  conven-
tional  follow-up  showed  that  a  survival  beneﬁt  was  observed
(odds  ratio  0.65;  p=0.021)  only in the  subset  of three  trials
with  daily  veriﬁcation  of  transmission,  as  is  performed  in our
center.  In  addition,  a  graded  relationship  between  adher-
ence  to  RM  and improved  survival  was  observed  in  a  recent
‘big  data’  study  of  269  471 implants  by  Varma  et  al.12
In  our  study,  patients  with  concomitant  CRT were
excluded.  This  population  could  conceivably  derive  a
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similar  or  larger  clinical  beneﬁt  from  RM,  owning  to  the
added  complexity  of  their  outpatient  management.  How-
ever,  the  effect  of  CRT  on  disease  history  and the variability
in  echocardiographic  and  clinical  responses  to  CRT would
make  it  more  difﬁcult  to  ascertain  the  exact  effect  of  RM  in
these  patients.  In  our study,  patients  who  were  subsequently
upgraded  to  an ICD-CRT  were  censored  from  analysis  after
the procedure  to  exclude  a  potential  confounding  effect.
While  the  magnitude  of  the  effect  of  RM  on  HF  admission
and  CV  mortality  in our  study  is  surprising,  it is  similar  to  pre-
vious  reports  such  as  the  IN-TIME  study  and the ALTITUDE
survival  registry.  Suggested  mechanisms  for the mortality
beneﬁt  observed  with  RM  include  earlier  notiﬁcation  of
adverse  events,  increased  patient  involvement  in their  own
healthcare,  and  a  more  comprehensive  assessment  of the
cardiac  health  and arrhythmia  status  of each patient.  In  any
case,  our  data  support  the notion  that  RM  is  certainly  not
harmful,  and  may  have  a  beneﬁcial  long-term  impact  on
overall  mortality,  which appears  to  stem  mainly  from  lower
cardiovascular  mortality  and a  reduction  in  the incidence  of
hospitalizations  for  HF,  a well-recognized  adverse  prognostic
factor.
Limitations
This  was  a  single-center  non-randomized  study,  and  thus
the generalizability  of our  results  is  limited.  As  this  was
a  retrospective  cohort  trial,  we  cannot  exclude  the  effect
of  unmeasured  confounders  or  some degree  of  bias;  in
particular,  although  there  were no  signiﬁcant  differences
between  the  groups  after  propensity  score  matching,  we
cannot  exclude  the  potential  effect  of indication  bias.  In
addition,  since  patients  had  to  agree  to the  use  of  RM,  we
could  hypothesize  that  some  of  those  who  refused  RM also
had  lower  adherence  to  other  measures  (such  as  medica-
tion),  which  could  make  RM  a surrogate  for  non-adherence.
However,  the  measured  patient  characteristics  were  well
balanced  between  groups at baseline,  and  the magnitude
and  temporal  consistency  of  the clinical  beneﬁt  in the RM
group  suggest  a  more  signiﬁcant  effect  than  what  would  be
explained  by  lower  compliance.  In addition,  the use  of  ‘hard’
endpoints  (hospitalization  or  death)  and  of  a publicly  avail-
able  database  reduces  the  possibility  of under-reporting  of
events  in  the  conventional  follow-up  group  as  compared  to
the  RM  group.
Finally,  our  study  was  designed  to assess the impact  of
device-based  RM,  as performed  in daily  practice,  on  rele-
vant  clinical  events.  However,  since  there  was  no  systematic
assessment  of  the cause  of RM  alerts  or  transmissions,  we
cannot  report  on  the speciﬁc  relevance  of  the different  mon-
itored  parameters  such as  thoracic  impedance  or  detection
of  atrial  ﬁbrillation.
Conclusions
In a  propensity  score-matched  cohort  of  ICD  recipients  with
long-term  follow-up,  RM  was  associated  with  a lower  rate  of
a  composite  outcome  of  hospital  admission  for  HF  or  cardio-
vascular  death.  Larger,  appropriately  powered  randomized
clinical  trials  are  warranted  to  deﬁnitely  establish  whether
device-based  RM  can lead  to  improved  outcomes  in  this high-
risk  population.
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